Investor Presentaiton

Company overview Financial performance Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials References Abbreviations Net debt increased by USD 8.6bn mainly due to the annual dividend payment and share buybacks (USD bn) -0.9 -7.5 -0.9 -8.6 -9.5 0.8 -5.2 4.2 Dec 31, 2021 Dividends M&A transactions Treasury share transactions, net Free Cash Flow Others June 30, 2022 35 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation